Ultimately, future studies will reveal whether Tfeb and/or Tfe3 deletion is sufficient to reduce renal tumorigenesis in mice with spontaneous or inducible loss of Tsc2, and establish whether MiT/TFE targeting could be therapeutically useful in the setting of human tuberous sclerosis. Here, TSC2 is linked to tuberous sclerosis.